Specifically, the c‐Abl inhibitors bafetinib (aka INNO‐406), radotinib and nilotinib block inactivation of parkin by c‐Abl and protect against neurotoxicity in mouse models of PD.61, 67, 68, 69. This evidence concerns the gene PRKN and Parkinson disease.